多奈哌齐联合阿托伐他汀治疗中重度阿尔茨海默病的疗效和安全性

摘要

Objective To explore the efficacy and safety of Donepezil combined with Atrovastatin on patients with moderate or severe Alzheimer disease.Methords Forty-four patients with moderate or severe Alzheimer disease were randomly divided into combination ( Donepezil combined with Atrovstatin ) group and Donepezil group.Results of blood lipid level, Mini-Mental State Examination ( MMSE), activity of daily living(ADL) and global deterioration scale(GDS) were compared respectively between the two groups before and after treatment.Results There was significant difference in the blood lipid level of combination group before and after treatment ( P ＜0.05 ) ,while not of Donepezil group ( P ＞ 0.05 ).There were significant differences in scores of MMSE, ADL and GDS of the two groups before and after treatment ( P ＜ 0.05 ).Improvements in scores of MMSE, ADL and GDS were significantly greater in combination group than those in Donepezil group statistically ( P ＜ 0.05 ).Conclusions Donepezil can improve effectively the cognitive and daily living skills of moderate or severe Alzheimer disease.The combination of Donepezil and Atrovstatin with high safety is superior to single use of Donepezil.%目的 探讨多奈哌齐联合阿托伐他汀治疗中、重度阿尔茨海默病(Alzheimer disease,AD)患者的疗效及安全性.方法 44例中、重度AD患者采用随机数字表法分为联合用药组和多奈哌齐组.治疗前和治疗24周后分别进行血脂水平、简易精神状态量表(Mini-Mental State Examination,MMSE)、日常生活能力量表(activity of daily living,ADL)及全面衰退量表(global deterioration scale,GDS)的检测和评分,并进行比较.结果 联合用药组治疗前后的血脂水平差异有统计学意义(P< 0.05),而多奈哌齐组则无统计学意义(P>0.05);每组治疗前后的MMSE、ADL及GDS评分比较,差异均有统计学意义(P<0.05);两组治疗后的各项评分比较,差异同样有统计学意义(P<0.05).结论 多奈哌齐联合阿托伐他汀能有效改善中、重度AD患者的认知功能和日常生活能力,效果优于单独使用多奈哌齐,且安全性高.